Albumin vs. non-protein colloids for fluid resuscitation: does it matter?

References

• Human albumin solutions: consensus statements for use in selected clinical situations. Subcommittee of the Victorian Drug Usage Advisory Committee. Med. J. Aust. 1992; 157:340–343.
   Google Scholar
• Vermeulen LC Jr, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA. A paradigm for consensus: The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern. Med. 1995; 155: 373–379.
   Google Scholar
• Audibert G, Charpentier C, Savoye E, Laxenaire MC. Use of albumin and other plasma substitutes from 1989 to 1993 in a French University hospital. Ann. Fr. Anesth. Reanim. 1995; 14: 517–522.
   PubMed Web of Science ®Google Scholar
• Bo1dt J, Lenz M, Kumle B, Papsdorf M. Volume replacement strategies on intensive care units: results from a postal survey. Inten. Care Med. 1998; 24: 147–151.
   Google Scholar
• Adams HA, Piepenbrod( S, Hempelmann G. Volume replacement solutions-pharmacology and clinical use. Anasthesiol. Intensivmed. Notfallmed. Schmerzther. 1998; 33: 2–17.
   PubMedGoogle Scholar
• Roberts JS, Bratton SL. Colloid volume expanders. Problems, pitfalls and possibilities. Drugs 1998; 55: 621–630.
   Google Scholar
• Landis EM, Pappenheimer JR. Exchanges of substances through the capillary walls. In: Dow P (ed) Handbook of Physiological Knowledge and Concepts. Baltimore: Williams and Wilkins; 1963, pp. 961–984.
   Google Scholar
• Kaminski MV Jr, Haase TJ. Albumin and colloid osmotic pressure implications for fluid resuscitation. Crit. Care Clin. 1992; 8: 311–321.
   PubMed Web of Science ®Google Scholar
• Guyton AC. Capillary dynamics and exchange of fluid between the blood and the interstital fluid. In: Guyton A (ed) Textbook of Medical Physiology. Philadelphia: WB Saunders; 1986, pp. 348–356.
   Google Scholar
• Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K. All medium starches are not the same: influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation. Transfusion 1996; 36: 450–455.
   PubMed Web of Science ®Google Scholar
• Brecher ME, Owen HG, Bandarenko N. Alternatives to albumin: starch replacement for plasma exchange. J. Clin. Apheresis 1997; 12: 146–153.
   Google Scholar
• London MJ, Franks M, Verrier ED, Merrick SH, Levin J, Mangano DT. The safety and efficacy of ten percent pentastarch as a cardiopulmonary bypass priming solution. A randomized clinical trial. J. Thorac. Cardiovasc. Surg. 1992; 104: 284–296.
   PubMed Web of Science ®Google Scholar
• Hulse JD, Yacobi A. Hetastarch: An overview of the colloid and its metabolism. Drug Intell. Clin. Pharm. 1983; 17: 334–341.
   PubMedGoogle Scholar
• Treib J, Haass A, Pindur G, et al. Highly substituted hydroxyethyl starch (HES 200/0.62) leads to Type-I von Willebrand syndrome after repeated administration. Haemostasis 1996; 26: 210–213.
   Google Scholar
• Langer R, Jordan U, Wolfle A, Henrich HA. Action of hydroxyethyl starch (HES) on the activity of plasmatic clotting factors. Clin. Hemorheol. Microcirc. 1998; 18: 103–116.
   PubMed Web of Science ®Google Scholar
• Cope JT, Banks D, Mauney MC, et al. Intraoperative hetastarch infusion impairs hemostasis after cardiac operations. Ann. Thorac. Surg. 1997; 63: 78–83.
   PubMed Web of Science ®Google Scholar
• Legendre CH, Thervet E, Page B, Percheron A, Noel LH, Kreis H. Hydroxyethyl starch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993; 342: 248–249.
   PubMed Web of Science ®Google Scholar
• Biguzas M, Jablonski P, Thomas AC, et al. Evaluation of LTW solution in a rat kidney preservation model. I. Effect of hydroxyethyl starch and electrolyte composition. Transplantation 1990; 49: 872–875.
   Google Scholar
• Vogt NH, Bothner U, Lerch G, Lindner KH, Georgieff M. Large-dose administration of 6% hydroxyethyl starch 200/ 0.5 total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin. Anesth Analg. 1996;83: 262–268.
   Google Scholar
• Vogt N, Brinkmann A, Georgieff M . The effect of HES, dextran and gelatin on kidney function [in German]. Andsthesiol. Intensivmed. Notfallmed. Schmerzther. 1998; 33: 268–270.
   PubMedGoogle Scholar
• Dieterich HJ, Kraft D, Sirtl C, et al. Hydroxyethyl starch antibodies in humans: incidence and clinical relevance. Anesth. Analg. 1998; 86: 1123–1126.
   PubMed Web of Science ®Google Scholar
• Cox NH, Popple AW. Persistent erythema and pruritus, with a confluent histiocytic skin infiltrate, following the use of a hydroxyethyl starch plasma expander. Br. J. Dermatol. 1996; 134: 353–357.
   PubMed Web of Science ®Google Scholar
• Dienes HP, Gerharz CD, Wagner R, Weber M, John HD. Accumulation of hydroxyethyl starch (HES) in the liver of patients with renal failure and portal hypertension. J. Hepatol. 1986; 3: 223–227.
   Google Scholar
• Guidet B, Podevin P, Robert A, Chauvin P. Maury E, Offenstadt G. High doses of hydroxyethyl starch and human albumin have similar effects on monocyte function and oncotic pressure. Fur. J. Clin. Invest. 1997; 27: 943–947.
   Web of Science ®Google Scholar
• Dewachter P, Laxenaire MC, Donner M, Kurtz M, Stoltz JF. In vivo rheologic studies of plasma substitutes [in French]. Ann. Fr. Anesth. Reanim. 1992; 11: 516–525.
   PubMedGoogle Scholar
• Mortier E, Ongenae M, De Baerdemaeker L, et al. In vitro evaluation of the effect of profound haemodilution with hydroxyethyl starch 6%, modified fluid gelatin 4% and dextran 40 10% on coagulation profile measured by thromboelastography. Anaesthesia 1997; 52: 1061–1064.
   PubMed Web of Science ®Google Scholar
• Salmon JB, Mythen MG. Pharmacology and physiology of colloids. Blood Rev. 1993; 7: 114–120.
   PubMed Web of Science ®Google Scholar
• Ljungstrom KG, Willman B, Hedin H. Hapten inhibition of dextran anaphylaxis. Nine years of post-marketing surveillance of dextran 1. Ann. Fr. Anesth. Reanim. 1993; 12: 219–222.
   Google Scholar
• Nearman HS, Herman ML. Toxic effects of colloids in the intensive care unit. Crit. Care Clinics 1991; 7: 713–723.
   PubMed Web of Science ®Google Scholar
• de Jonge E, Levi M, Berends F, van der Ende AE, ten Cate JW, Stoutenbeek CP. Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb. Haemost. 1998; 79: 286–290.
   Google Scholar
• Mardel SN, Saunders FM, Allen H, et al. Reduced quality of clot formation with gelatin-based plasma substitutes. Br. J. Anaesth. 1998; 80: 204–207.
   PubMed Web of Science ®Google Scholar
• Laxenaire MC, Charpentier C, Feldman L. [Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study. Ann. Fr. Anesth. Reanim. 1994; 13: 301–310.
   Google Scholar
• Schrieber R, Seybold U. Gelatine production, the six steps to maximum safety. Dev. Biol. Stand. 1993; 80: 195–198.
   PubMedGoogle Scholar
• Johnson SD, Lucas CE, Gerrick SJ, Ledgerwood AM, Higgins RE. Altered coagulation after albumin supplements for treatment of oligemic shock. Arch. Surg. 1979; 114: 379–383.
   Google Scholar
• Holt ME, Ryan ME, Campbell AK. Albumin inhibits human polymorphonuclear leucocyte luminol-dependent chemiluminescence: evidence for oxygen radical scavenging. Br. J. Exp. Pathol. 1984; 65: 231–241.
   Google Scholar
• Kovalik SG, Ledgerwood AM, Lucas CE, Higgins RE. The cardiac effect of altered calcium homeostasis after albumin resuscitation. J. Trauma 1981; 21: 275–279.
   PubMed Web of Science ®Google Scholar
• McClelland DBL. Safety of human albumin as a constituent of biologic therapeutic products. Transfusion 1998; 38: 690–699.
   PubMed Web of Science ®Google Scholar
• Chandra S, Cavanaugh JE, Lin CM. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments. Transfusion 1999; 39: 249–257.
   Google Scholar
• Cuthbertson B, Rennie JG, Aw D, Reid KG. Safety of albumin preparations manufactured from plasma not tested for HIV antibody. Lancet 1987; 2: 41.
   PubMed Web of Science ®Google Scholar
• Nowak T, Gregersen JP, Klockmann U, Cummins LB, Hilfenhaus J. Virus safety of human immunoglobulins: Efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure. J. Med.Virol. 1992; 36: 209–216.
   Google Scholar
• Hauser CJ, Shoemaker WC, Turpin I, Goldberg SJ. Oxygen transport responses to colloids and crystalloids in critically ill surgical patients. Surg. Gynecol. Obstet. 1980; 150: 811–816.
   PubMedGoogle Scholar
• Griffel MI, Kaufman BS. Pharmacology of colloids and crystalloids. Crit. Care Clin. 1992; 8: 235–253.
   PubMed Web of Science ®Google Scholar
• American Society of Anesthesiologists. Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996; 84: 732–747.
   PubMed Web of Science ®Google Scholar
• Beyer R, Harmening U, Rittmeyer 0, etal. Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery. Br. J. Anaesth. 1997; 78: 44–50.
   Google Scholar
• Rackow EC, Falk JL, Fein IA, et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit. Care Med. 1983; 11: 839–50.
   PubMed Web of Science ®Google Scholar
• Lucas CE, Ledgerwood AM, Higgins RF, Weaver DW. Impaired pulmonary function after albumin resuscitation from shock. J. Trauma 1980; 20: 446–451.
   PubMed Web of Science ®Google Scholar
• Grootendorst AF, van Wilgenburg MG, de Laat PH, van der Hoven B. Albumin abuse in intensive care medicine. In ten. Care Med. 1988; 14: 554–557.
   PubMed Web of Science ®Google Scholar
• Zadrobilek E, Hackl W, Sporn P. Steinbereithner K. Effect of large volume replacement with balanced electrolyte solutions on extravascular lung water in surgical patients with sepsis syndrome. In ten. Care Med. 1989;15: 505–510.
   Google Scholar
• Baron JF, Delayance S. Threshold values of colloid-osmotic pressure, serum albumin or protein during perioperative period. Ann. Fr. Anesth. Reanim. 1996; 15: 447–455.
   PubMed Web of Science ®Google Scholar
• Rackow EC, Fein IA, Siegel J. The relationship of the colloid osmotic-pulmonary artery wedge pressure gradient to pulmonary oedema and mortality in critically ill patients. Chest. 1982; 82: 433–437.
   Google Scholar
• Mayer SA, Solomon RA, Fink ME, et al. Effect of 5% albumin solution on sodium balance and blood volume after subarachnoid hemorrhage. Neurosurgery. 1998; 42:759–768.
   PubMed Web of Science ®Google Scholar
• Huh PW, Belayev L, Zhao W, Busto R, Saul I, Ginsberg MD. The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res. 1998; 804: 105–113.
   PubMed Web of Science ®Google Scholar
• Fleck A, Raines G, Hawker F, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lancet 1985;1: 781–784.
   PubMed Web of Science ®Google Scholar
• McClain CJ, Hennig B, Ott LG, Goldblum S, Young AB. Mechanisms and implications of hypoalbuminemia inhead-injured patients. J. Neurosurg. 1988; 69: 386–392.
   Google Scholar
• Kaminski MV Jr, Williams SD. Review of the rapid normalization of serum albumin with modified total parenteral nutrition solutions. Crit. Care Med. 1990; 18: 327–335.
   PubMed Web of Science ®Google Scholar
• Human albumin administration in critically ill patients: Systematic review of randomised controlled trials. BMJ 1998; 317: 235–340.
   PubMed Web of Science ®Google Scholar
• Watts J. Comparing different studies is difficult. BMJ 1998; 317: 277.
   PubMed Web of Science ®Google Scholar
• Makin A, Plenderleith L. Onc conclusion could be that hypertonic saline is better than colloids in trauma. BMJ 1998; 317: 277.
   PubMed Web of Science ®Google Scholar
• McAnulty G, Grounds R. Eight studies should have been excluded. BMJ 1998; 317: 277.
   Google Scholar
• Bapat P. Raine G. Use of dextran-70 for fluid resuscitation has been dying out. BMJ 1998; 317: 277.
   Google Scholar
• Manelli JC. Is albumin administration useful in critical care for burnt patients? Ann. Fr. Anesth. Reanim. 1996; 15: 507–513.
   PubMedGoogle Scholar
• Goodwin CW, Dorethy J, Lam V, Pruitt BA Jr. Randomized trial of efficacy of crystalloid and colloid resuscitation on hemodynamic response and lung water following thermal injury. Ann. Surg. 1983; 197: 520–531.
   Google Scholar
• Demling HR. Burn care in the immediate resuscitation period. In: Scientific American Surgery. New York: Scientific American, Inc. 1998, pp. 1–16.
   Google Scholar
• Sanchez R. Role of albumins in burnt patients: its efficacy during intensive care. Addendum to the expert guidelines of the Consensus Conference, Paris, December 15th, 1995. Ann. Fr. Anesth. Reanim. 1996; 15: 1124–1129.
   Google Scholar
• Carsin H. Human albumin solutions in the treatment of burned patients. Current indications. Presse Med. 1997; 26: 474–476.
   PubMed Web of Science ®Google Scholar
• Fiorica JV, Roberts WS, Hoffman MS, et al. Concentrated albumin infusion as an aid to postoperative recovery after pelvic exenteration. Gynecol. Oncol. 1991; 43: 265–269.
   PubMed Web of Science ®Google Scholar
• Camu F, Ivens D, Christiaens F. Human albumin and colloid fluid replacement: their use in general surgery. Acta Anaesthesiol. Belg. 1995; 46: 3–18.
   Google Scholar
• Sade RM, Stroud MR, Crawford FA Jr, Kratz JM, Dearing JP, Bartles DM. A prospective randomized study of hydroxyethyl starch, albumin, and lactated Ringer's solution as priming fluid for cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 1985; 89: 713–722.
   PubMed Web of Science ®Google Scholar
• Hoeft A, Korb H, Mehlhorn U, Stephan H, Sonntag H. Priming of cardiopulmonary bypass with human albumin or Ringer lactate: effect on colloid osmotic pressure and extravascular lung water. Br. J. Anaesth. 1991; 66: 73–80.
   Google Scholar
• Hisatomi K, Isomura T, Hayashida N, Sato T, Kosuga K, Aoyagi S. Effect of the addition of albumin to crystalloid cardioplegic solutions on myocardial metabolism in infants undergoing open heart surgery. Surg. Today 1996; 26: 395–399.
   PubMed Web of Science ®Google Scholar
• Tigchelaar I, Gallandat Huet RC, Korsten J, Boonstra PW, van Oeveren W. Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass. Fur. J. Cardiothorac. Surg. 1997; 11: 626–632.
   Web of Science ®Google Scholar
• Himpe D, Van Cauwelaert P, Neels H, et al. Priming solutions for cardiopulmonary bypass: comparison of three colloids. J. Cardiothorac. Vasc. Anesth. 1991; 5: 457–466.
   PubMedGoogle Scholar
• London MJ, Ho JS, Triedman JK, et al. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J. Thorac. Cardiovasc. Surg. 1989; 97: 785–797.
   PubMed Web of Science ®Google Scholar
• Bo1dt J, Knothe C, Zickmann B, Andres P, Dapper F, Hempelmann G. Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesth. Analg. 1993; 76: 1185–1190.
   Google Scholar
• Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680–1697.
   PubMed Web of Science ®Google Scholar
• Nuttall GA, Oliver WC, Ereth MI-I, Santrach PJ. Coagulation tests predict bleeding after cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. 1997; 11: 815–823.
   PubMed Web of Science ®Google Scholar
• Gines P, Arroyo V. Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234–241.
   PubMed Web of Science ®Google Scholar
• Gines P. Tito L, Arroyo V. et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493–1502.
   PubMed Web of Science ®Google Scholar
• Altman C, Bernard B, Roulot D, Vitte R-L, Ink 0. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Fur. J. Gastroenterol. Hepatol. 1998; 10: 5–10.
   Google Scholar
• Gines P. Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002–1010.
   Google Scholar
• Sola R, Vila MC, Andreu M, et al. Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. J. Hepatol. 1994; 20: 282–288.
   PubMed Web of Science ®Google Scholar
• Stegmayr BG. Plasma exchange in patients with septic shock including acute renal failure. Blood Purif. 1996; 14: 102–108.
   PubMed Web of Science ®Google Scholar
• Moreau R, Valla D. Indications and role of albumin, plasma volume expansion excluded, in the preoperative or postoperative management of portal hypertension. Ann. Fr. Anesth. Reanim. 1996; 15: 514–524.
   PubMed Web of Science ®Google Scholar
• Vercauteren M, Hoffmann V. Coppejans H, Van Steenberge A, Adriaensen H. Hydroxyethylstarch compared with modified gelatin as volume preload before spinal anaesthesia for Caesarean section. Br. J. Anaesth. 1996; 76: 731–733.
   Google Scholar
• Guggiari M, Georgescu H. [The injured brain. Basis for hydroelectrolytic and hemodynamic resuscitation]. Ann. Fr. Anesth. Reanim. 1994; 13: 98–104.
   PubMed Web of Science ®Google Scholar
• Tomita H, Ito U, Tone 0, Masaoka H, Tominaga B. High colloid oncotic therapy for contusional brain edema. Acta. Neurochir. Sup p1. (Wien). 1994; 60: 547–549.
   PubMedGoogle Scholar